TLE2

Summary

TLE2 (TLE family member 2, transcriptional corepressor, HGNC:11838) is a protein-coding gene on chromosome 19p13.3, encoding Transducin-like enhancer protein 2 (Q04725). Transcriptional corepressor that binds to a number of transcription factors.

Enables transcription corepressor activity. Involved in negative regulation of DNA-templated transcription and negative regulation of canonical Wnt signaling pathway. Located in focal adhesion and nuclear body.

Source: NCBI Gene 7089 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 155 total
• Phenotypes (HPO): 2
• MANE Select transcript: NM_003260

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11838
Approved symbol	TLE2
Name	TLE family member 2, transcriptional corepressor
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	ESG2, GRG2, ESG, FLJ41188
Ensembl gene	ENSG00000065717
Ensembl biotype	protein_coding
OMIM	601041
Entrez	7089

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 15 protein_coding, 6 retained_intron, 5 protein_coding_CDS_not_defined

ENST00000262953, ENST00000426948, ENST00000443826, ENST00000586422, ENST00000586492, ENST00000587137, ENST00000587217, ENST00000587672, ENST00000587770, ENST00000587893, ENST00000589205, ENST00000589291, ENST00000589364, ENST00000590101, ENST00000590183, ENST00000590536, ENST00000591457, ENST00000591529, ENST00000591720, ENST00000592305, ENST00000592584, ENST00000881232, ENST00000958737, ENST00000958738, ENST00000958739, ENST00000958740

RefSeq mRNA: 4 — MANE Select: NM_003260 NM_001144761, NM_001144762, NM_001300846, NM_003260

CCDS: CCDS45911, CCDS45912, CCDS45913, CCDS74255

Canonical transcript exons

ENST00000262953 — 20 exons

Exon	Start	End
ENSE00000663892	3008869	3008945
ENSE00000663897	3000647	3000723
ENSE00000859585	3002353	3002503
ENSE00001149506	3006420	3006669
ENSE00001149523	3009542	3009702
ENSE00001724845	3005721	3005968
ENSE00001792487	3005437	3005584
ENSE00002210673	3028881	3029280
ENSE00002885593	2997644	2997955
ENSE00003466678	3025020	3025082
ENSE00003472047	3028319	3028382
ENSE00003480455	3013669	3013818
ENSE00003499703	3028706	3028803
ENSE00003509679	3019699	3019773
ENSE00003523475	3014570	3014614
ENSE00003532336	3017840	3017859
ENSE00003607265	3011022	3011160
ENSE00003638864	3015653	3015760
ENSE00003654994	3027829	3027873
ENSE00003673556	3019283	3019463

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 99.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.5996 / max 517.3361, expressed in 1111 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178224	4.3107	861
178225	3.1118	854
178223	0.0684	23
178221	0.0682	35
178222	0.0405	24

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar hemisphere	UBERON:0002245	99.32	gold quality
cerebellar cortex	UBERON:0002129	99.31	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.26	gold quality
cerebellum	UBERON:0002037	99.05	gold quality
cerebellar vermis	UBERON:0004720	98.64	gold quality
nerve	UBERON:0001021	97.99	gold quality
tibial nerve	UBERON:0001323	97.99	gold quality
right lobe of thyroid gland	UBERON:0001119	97.70	gold quality
left lobe of thyroid gland	UBERON:0001120	97.54	gold quality
left uterine tube	UBERON:0001303	97.27	gold quality
thyroid gland	UBERON:0002046	97.08	gold quality
parotid gland	UBERON:0001831	96.97	gold quality
apex of heart	UBERON:0002098	96.93	gold quality
sural nerve	UBERON:0015488	96.89	gold quality
body of uterus	UBERON:0009853	96.86	gold quality
right atrium auricular region	UBERON:0006631	96.54	gold quality
paraflocculus	UBERON:0005351	96.29	gold quality
cardiac atrium	UBERON:0002081	95.99	gold quality
saliva-secreting gland	UBERON:0001044	95.65	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.49	gold quality
minor salivary gland	UBERON:0001830	95.16	gold quality
endocervix	UBERON:0000458	94.84	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.55	gold quality
myometrium	UBERON:0001296	94.53	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.29	gold quality
trigeminal ganglion	UBERON:0001675	94.07	gold quality
metanephros cortex	UBERON:0010533	93.99	gold quality
lower esophagus muscularis layer	UBERON:0035833	93.99	gold quality
lower esophagus	UBERON:0013473	93.97	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.95	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.74

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HLF, PROP1, TCF3

miRNA regulators (miRDB)

18 targeting TLE2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-422A	99.18	65.83	550
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-4764-5P	98.88	65.53	894
HSA-MIR-331-3P	98.76	64.91	793
HSA-MIR-378A-3P	98.43	66.10	548
HSA-MIR-378B	98.43	65.36	573
HSA-MIR-378C	98.43	66.10	548
HSA-MIR-378D	98.43	66.10	548
HSA-MIR-378E	98.43	65.99	551
HSA-MIR-378F	98.43	65.66	554
HSA-MIR-378H	98.43	66.16	545
HSA-MIR-378I	98.43	66.10	548
HSA-MIR-6810-3P	97.96	64.57	1023
HSA-MIR-5571-3P	97.80	66.07	640
HSA-MIR-2278	97.30	66.19	1130
HSA-MIR-4435	95.90	65.47	1201

Literature-anchored findings (GeneRIF, showing 1)

• Immunofluorescence analysis showed that TLE2 and RTA were colocalized in the same nuclear compartment in KSHV-infected cells. (PMID:19939918)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tle2b	ENSDARG00000008767
danio_rerio	tle2a	ENSDARG00000042484
danio_rerio	tle2c	ENSDARG00000067832
mus_musculus	Tle2	ENSMUSG00000034771
rattus_norvegicus	Tle2	ENSRNOG00000005874

Paralogs (6): TLE6 (ENSG00000104953), TLE5 (ENSG00000104964), TLE4 (ENSG00000106829), TLE3 (ENSG00000140332), TLE1 (ENSG00000196781), TLE7 (ENSG00000260734)

Protein

Protein identifiers

Transducin-like enhancer protein 2 — Q04725 (reviewed: Q04725)

Alternative names: Enhancer of split groucho-like protein 2

All UniProt accessions (7): Q04725, K7EJR7, K7EK93, K7EMK7, K7EPD4, K7EPF3, K7ESD8

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional corepressor that binds to a number of transcription factors. Inhibits the transcriptional activation mediated by CTNNB1 and TCF family members in Wnt signaling. The effects of full-length TLE family members may be modulated by association with dominant-negative AES.

Subunit / interactions. Homooligomer and heterooligomer with other family members. Binds LEF1, TCF7, TCF7L1, TCF7L2, UTY, HES1 and HES5.

Subcellular location. Nucleus.

Tissue specificity. In all tissues examined, mostly in heart, brain, and muscle.

Post-translational modifications. Ubiquitinated by XIAP/BIRC4.

Domain organisation. WD repeat Groucho/TLE family members are characterized by 5 regions, a glutamine-rich Q domain, a glycine/proline-rich GP domain, a central CcN domain, containing a nuclear localization signal, and a serine/proline-rich SP domain. The most highly conserved are the N-terminal Q domain and the C-terminal WD-repeat domain.

Similarity. Belongs to the WD repeat Groucho/TLE family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q04725-1	1	yes
Q04725-2	2
Q04725-3	3

RefSeq proteins (4): NP_001138233, NP_001138234, NP_001287775, NP_003251* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR005617	Groucho/TLE_N	Domain
IPR009146	Groucho_enhance	Family
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily

Pfam: PF00400, PF03920

UniProt features (34 total): region of interest 7, sequence conflict 7, repeat 6, splice variant 5, modified residue 4, compositionally biased region 2, chain 1, short sequence motif 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q04725-F1	68.40	0.41

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 228, 249, 253, 281

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex
R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-3769402	Deactivation of the beta-catenin transactivating complex
R-HSA-4641265	Repression of WNT target genes

MSigDB gene sets: 148 (showing top): REACTOME_SIGNALING_BY_NOTCH, BENPORATH_ES_WITH_H3K27ME3, XU_GH1_AUTOCRINE_TARGETS_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A5, MODULE_66, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, MODULE_88, MODULE_6, MODULE_11, MODULE_60, MODULE_38

GO Biological Process (6): signal transduction (GO:0007165), animal organ morphogenesis (GO:0009887), Wnt signaling pathway (GO:0016055), negative regulation of DNA-templated transcription (GO:0045892), negative regulation of canonical Wnt signaling pathway (GO:0090090), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (2): transcription corepressor activity (GO:0003714), protein binding (GO:0005515)

GO Cellular Component (6): obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), focal adhesion (GO:0005925), nuclear body (GO:0016604)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
TCF dependent signaling in response to WNT	2
Signaling by NOTCH1	1
Degradation of beta-catenin by the destruction complex	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
anatomical structure morphogenesis	1
animal organ development	1
cell surface receptor signaling pathway	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
negative regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription coregulator activity	1
negative regulation of DNA-templated transcription	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
protein-containing complex	1
cell-substrate junction	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

750 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TLE2	HLF	Q16534	755
TLE2	SRPX2	O60687	667
TLE2	PIK3R1	P27986	656
TLE2	A0A087WTN9	A0A087WTN9	639
TLE2	DBP	Q10586	586
TLE2	TFPT	P0C1Z6	559
TLE2	PPP1R3A	Q16821	557
TLE2	RUNX1	Q01196	547
TLE2	ASTN2	O75129	547
TLE2	FBXO40	Q9UH90	543
TLE2	TEF	Q10587	541
TLE2	CDH9	Q9ULB4	540
TLE2	CTNNB1	P35222	535
TLE2	CDH10	Q9Y6N8	532
TLE2	GRB2	P29354	518

IntAct

44 interactions, top by confidence:

A	B	Type	Score
CTNNBIP1	APC	psi-mi:“MI:0914”(association)	0.740
TLE2	CCT6A	psi-mi:“MI:0914”(association)	0.640
RIPPLY1	TLE2	psi-mi:“MI:0914”(association)	0.530
RIPPLY2	TLE2	psi-mi:“MI:0914”(association)	0.530
TLE2	TCP1	psi-mi:“MI:0914”(association)	0.530
TLE4	TLE1	psi-mi:“MI:0914”(association)	0.530
LYZL6	COL6A1	psi-mi:“MI:0914”(association)	0.530
TLE2	HSPA8	psi-mi:“MI:0914”(association)	0.530
DDB1	TLE2	psi-mi:“MI:0915”(physical association)	0.500
NUDC	TLE2	psi-mi:“MI:0915”(physical association)	0.400
TLE2	VENTX	psi-mi:“MI:0915”(physical association)	0.370
TLE2	TLX3	psi-mi:“MI:0915”(physical association)	0.370
TLE2	BARHL1	psi-mi:“MI:0915”(physical association)	0.370
EMX2	TLE2	psi-mi:“MI:0915”(physical association)	0.370
FOXA3	TLE2	psi-mi:“MI:0915”(physical association)	0.370
MSX1	TLE2	psi-mi:“MI:0915”(physical association)	0.370
MSX2	TLE2	psi-mi:“MI:0915”(physical association)	0.370
PAX9	TLE2	psi-mi:“MI:0915”(physical association)	0.370
CUL4B	TLE1	psi-mi:“MI:0914”(association)	0.350
CUL4B	TLE2	psi-mi:“MI:0914”(association)	0.350
TLE2	CUL4B	psi-mi:“MI:0914”(association)	0.350
TLE3	ATP2A1	psi-mi:“MI:0914”(association)	0.350
HLX	SCAF4	psi-mi:“MI:0914”(association)	0.350
TLE4	TLE2	psi-mi:“MI:0914”(association)	0.350
DCAF4	IGLL5	psi-mi:“MI:0914”(association)	0.350
MFAP4	CRLF1	psi-mi:“MI:0914”(association)	0.350
RIPPLY3	A2ML1	psi-mi:“MI:0914”(association)	0.350
EN1	MEIS1	psi-mi:“MI:0914”(association)	0.350
ANKRD50	PPP1R12A	psi-mi:“MI:0914”(association)	0.350
MFAP4	PEX1	psi-mi:“MI:0914”(association)	0.350

BioGRID (425): TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), TLE2 (Two-hybrid), TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), TLE2 (Affinity Capture-MS), CCT7 (Affinity Capture-MS), TLE2 (Affinity Capture-MS)

ESM2 similar proteins: A3KMV1, B9EHT4, D3YWQ0, D5SHR0, F1MAB7, F5HB62, O42406, O75426, O75592, O75912, O95343, P03177, P0C5J9, P42859, P51111, P59114, P59438, Q04725, Q08274, Q0VD00, Q1HVD1, Q2TAL5, Q3KSQ2, Q3V0G7, Q4G017, Q4R327, Q4VC12, Q5R686, Q5U464, Q5VVW2, Q6NRL1, Q6P7W2, Q7TPH6, Q80TM9, Q80VW5, Q810W9, Q8BFX3, Q8CH72, Q8CI12, Q8K0E1

Diamond homologs: A0A1W2PR48, O02482, O13166, O13168, O42469, O42478, P16371, Q04724, Q04725, Q04726, Q04727, Q07141, Q08122, Q62440, Q62441, Q9H808, Q9JIT3, Q9WVB2, Q9WVB3, A0A223GEB2, A1L271, A6H603, G4MQX3, O14775, P23232, P25387, P62881, P62882, Q01369, Q10051, Q149M9, Q5GIS3, Q5RDY7, Q61FW2, Q6NUD0, Q6PBY0, Q6PNB6, Q80ZD0, Q9BYB4, A0JMQ0

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
TLE2	down-regulates	LEF1	binding
PHF12	“up-regulates activity”	TLE2	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 44 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Deactivation of the beta-catenin transactivating complex	5	38.8×	3e-05

GO biological processes:

GO term	Partners	Fold	FDR
protein folding	6	14.1×	7e-04
negative regulation of canonical Wnt signaling pathway	5	13.4×	2e-03
Wnt signaling pathway	5	11.3×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

155 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	118
Likely benign	10
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3106 predictions. Top by Δscore:

Variant	Effect	Δscore
19:2997961:A:T	acceptor_gain	1.0000
19:3000643:GTACC:G	donor_loss	1.0000
19:3000644:TACC:T	donor_loss	1.0000
19:3000645:A:T	donor_loss	1.0000
19:3000723:CCT:C	acceptor_gain	1.0000
19:3000725:T:C	acceptor_gain	1.0000
19:3000725:T:TC	acceptor_gain	1.0000
19:3002368:T:TA	donor_gain	1.0000
19:3002384:G:C	donor_gain	1.0000
19:3002499:AAAAT:A	acceptor_gain	1.0000
19:3002500:AAAT:A	acceptor_gain	1.0000
19:3002501:AAT:A	acceptor_gain	1.0000
19:3002502:AT:A	acceptor_gain	1.0000
19:3002504:C:CC	acceptor_gain	1.0000
19:3002510:G:GC	acceptor_gain	1.0000
19:3005940:T:C	acceptor_gain	1.0000
19:3005964:CGGTT:C	acceptor_gain	1.0000
19:3005965:GGTT:G	acceptor_gain	1.0000
19:3005967:TT:T	acceptor_gain	1.0000
19:3005969:C:CA	acceptor_loss	1.0000
19:3005969:C:CC	acceptor_gain	1.0000
19:3005970:T:A	acceptor_loss	1.0000
19:3005976:C:CT	acceptor_gain	1.0000
19:3005977:G:T	acceptor_gain	1.0000
19:3013849:T:TC	acceptor_gain	1.0000
19:3014565:CTCA:C	donor_loss	1.0000
19:3014567:CA:C	donor_loss	1.0000
19:3014568:A:AC	donor_gain	1.0000
19:3014569:C:CC	donor_gain	1.0000
19:3014569:C:CT	donor_loss	1.0000

AlphaMissense

4826 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:2997891:C:T	G730D	1.000
19:3000679:A:G	W698R	1.000
19:3000679:A:T	W698R	1.000
19:3000703:C:A	G690W	1.000
19:3000707:G:C	S688R	1.000
19:3000707:G:T	S688R	1.000
19:3000709:T:G	S688R	1.000
19:3002498:G:C	F634L	1.000
19:3002498:G:T	F634L	1.000
19:3002500:A:G	F634L	1.000
19:3005485:C:A	W616C	1.000
19:3005485:C:G	W616C	1.000
19:3005487:A:G	W616R	1.000
19:3005487:A:T	W616R	1.000
19:3005504:T:A	D610V	1.000
19:3005504:T:G	D610A	1.000
19:3005505:C:G	D610H	1.000
19:3005511:C:G	G608R	1.000
19:3005513:C:T	G607E	1.000
19:3005514:C:A	G607W	1.000
19:3005551:G:C	C594W	1.000
19:3005554:G:C	S593R	1.000
19:3005554:G:T	S593R	1.000
19:3005556:T:G	S593R	1.000
19:3005561:C:T	G591D	1.000
19:3005574:C:G	G587R	1.000
19:3005749:A:G	W574R	1.000
19:3005749:A:T	W574R	1.000
19:3005751:A:T	V573D	1.000
19:3005763:C:A	G569V	1.000

dbSNP variants (sampled 300 via entrez): RS1000135067 (19:3016233 G>A), RS1000204481 (19:3030747 C>G), RS1000219547 (19:3043197 C>T), RS1000260471 (19:3010424 C>T), RS1000273671 (19:3001793 T>C), RS1000407448 (19:3048964 A>C), RS1000464638 (19:3016608 T>A), RS1000474893 (19:3031029 C>T), RS1000504053 (19:2999982 G>A), RS1000684649 (19:2997257 G>C), RS1000756326 (19:3024875 G>A), RS1000779583 (19:3041695 C>T), RS1000807593 (19:3020834 A>C,G), RS1000815547 (19:3033747 T>A), RS1000827487 (19:3006917 G>C,T)

Disease associations

OMIM: gene MIM:601041 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): neutropenia (MONDO:0001475), lymphopenia (MONDO:0003783)

Orphanet (0):

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0001875	Decreased total neutrophil count
HP:0001888	Decreased total lymphocyte count

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008231	Lymphopenia	C15.378.243.750.605; C15.378.553.546.605; C20.673.627
D009503	Neutropenia	C15.378.243.750.184.564; C15.378.553.546.184.564

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	increases expression, affects cotreatment	2
Arsenic Trioxide	decreases expression, increases expression	2
Nickel	decreases expression	2
Valproic Acid	increases expression, increases methylation	2
FR900359	increases phosphorylation	1
bisphenol A	decreases methylation	1
methylselenic acid	increases expression	1
sodium arsenite	decreases expression	1
aflatoxin B2	increases methylation	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Folic Acid	decreases expression	1
Hydrogen Peroxide	affects expression	1
Indomethacin	affects cotreatment, increases expression	1
Lead	affects expression	1
Phenobarbital	affects expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Progesterone	increases expression	1
Selenium	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D8X6	Ubigene HCT 116 TLE2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

199 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00030758	PHASE4	UNKNOWN	Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
NCT00125723	PHASE4	COMPLETED	FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
NCT00194857	PHASE4	TERMINATED	Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
NCT00257790	PHASE4	COMPLETED	The Tobramycin Study
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00686543	PHASE4	COMPLETED	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
NCT01086878	PHASE4	COMPLETED	Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
NCT01114165	PHASE4	COMPLETED	Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients
NCT01135589	PHASE4	UNKNOWN	Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation
NCT01571518	PHASE4	UNKNOWN	Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy
NCT02621905	PHASE4	COMPLETED	Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
NCT02967341	PHASE4	UNKNOWN	Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients
NCT04009941	PHASE4	COMPLETED	Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
NCT04904614	PHASE4	COMPLETED	Letermovir Use in Heart Transplant Recipients
NCT05626530	PHASE4	RECRUITING	Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
NCT06145321	PHASE4	ACTIVE_NOT_RECRUITING	Continuous Versus Bolus Administration of G-CSF in Children With Cancer
NCT00001338	PHASE3	COMPLETED	A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
NCT00001646	PHASE3	COMPLETED	Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
NCT00002658	PHASE3	UNKNOWN	Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
NCT00002719	PHASE3	COMPLETED	Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
NCT00003739	PHASE3	COMPLETED	Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy
NCT00020865	PHASE3	UNKNOWN	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
NCT00035594	PHASE3	COMPLETED	Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
NCT00044486	PHASE3	COMPLETED	Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
NCT00107081	PHASE3	TERMINATED	Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting
NCT00445497	PHASE3	UNKNOWN	Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
NCT00529282	PHASE3	TERMINATED	A Study of Ceftobiprole in Patients With Fever and Neutropenia.
NCT00627393	PHASE3	COMPLETED	Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
NCT00770172	PHASE3	COMPLETED	G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
NCT00784368	PHASE3	COMPLETED	A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
NCT00806351	PHASE3	TERMINATED	An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
NCT00911170	PHASE3	COMPLETED	PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
NCT01307579	PHASE3	COMPLETED	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
NCT01371656	PHASE3	COMPLETED	Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
NCT01560195	PHASE3	UNKNOWN	A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
NCT01611051	PHASE3	COMPLETED	A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
NCT02238873	PHASE3	UNKNOWN	Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
NCT02414581	PHASE3	COMPLETED	Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7%
NCT02643420	PHASE3	COMPLETED	SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
NCT02872103	PHASE3	COMPLETED	Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy